124 related articles for article (PubMed ID: 23666016)
21. Patterns and trends in human papillomavirus-related diseases in Central and Eastern Europe and Central Asia.
Bray F; Lortet-Tieulent J; Znaor A; Brotons M; Poljak M; Arbyn M
Vaccine; 2013 Dec; 31 Suppl 7():H32-45. PubMed ID: 24332296
[TBL] [Abstract][Full Text] [Related]
22. Health Economic Data Requirements and Availability in the European Union: Results of a Survey Among 10 European Countries.
Skoupá J; Annemans L; Hájek P
Value Health Reg Issues; 2014 Sep; 4():53-57. PubMed ID: 29702807
[TBL] [Abstract][Full Text] [Related]
23. First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis.
Neyt M; Vlayen J; Devriese S; Camberlin C
PLoS One; 2018; 13(4):e0195134. PubMed ID: 29630612
[TBL] [Abstract][Full Text] [Related]
24. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
25. Euroguidelines in Central and Eastern Europe (ECEE) conference and the Warsaw Declaration - a comprehensive meeting report.
Kowalska JD; Oprea C; de Witt S; Pozniak A; Gökengin D; Youle M; Lundgren JD; Horban A;
HIV Med; 2017 May; 18(5):370-375. PubMed ID: 27553526
[TBL] [Abstract][Full Text] [Related]
26. [Evaluation of the burden of diabetes in Poland].
Kissimova-Skarbek K; Pach D; Płaczkiewicz E; Szurkowska M; Szybiński Z
Pol Arch Med Wewn; 2001 Sep; 106(3):867-73. PubMed ID: 11928598
[TBL] [Abstract][Full Text] [Related]
27. From randomised clinical trials to clinical practice : a pragmatic cost-effectiveness analysis of Paclitaxel in first-line therapy for advanced ovarian cancer.
Limat S; Woronoff-Lemsi MC; Menat C; Madroszyk-Flandin A; Merrouche Y
Pharmacoeconomics; 2004; 22(10):633-41. PubMed ID: 15244489
[TBL] [Abstract][Full Text] [Related]
28. Schizophrenia causes significant burden to patients' and caregivers' lives.
Szkultecka-Dębek M; Miernik K; Stelmachowski J; Jakovljević M; Jukić V; Aadamsoo K; Janno S; Bitter I; Tolna J; Jarema M; Jankovic S; Pecenak J; Vavrusova L; Tavčar R; Walczak J; Talbot D; Augustyńska J
Psychiatr Danub; 2016 Jun; 28(2):104-10. PubMed ID: 27287783
[TBL] [Abstract][Full Text] [Related]
29. Access to novel cancer medicines in four countries in Central and Eastern Europe in relation to clinical benefit.
Hofmarcher T; Szilagyiova P; Gustafsson A; Dolezal T; Rutkowski P; Baxter C; Karamousouli E
ESMO Open; 2023 Aug; 8(4):101593. PubMed ID: 37413761
[TBL] [Abstract][Full Text] [Related]
30. Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain.
Ojeda B; de Sande LM; Casado A; Merino P; Casado MA
Br J Cancer; 2003 Sep; 89(6):1002-7. PubMed ID: 12966416
[TBL] [Abstract][Full Text] [Related]
31. Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601).
Decroisette C; Monnet I; Berard H; Quere G; Le Caer H; Bota S; Audigier-Valette C; Geriniere L; Vernejoux JM; Chouaid C;
J Thorac Oncol; 2011 Mar; 6(3):576-82. PubMed ID: 21270669
[TBL] [Abstract][Full Text] [Related]
32. A European survey on the insights of patients living with metastatic colorectal cancer: the patient journey before, during and after diagnosis - an Eastern European perspective.
Maravic Z; Rawicka I; Benedict A; Wyrwicz L; Horvath A; Fotaki V; Carrato A; Borras JM; Ruiz-Casado A; Petrányi A; Lemmens L; Espín-Basany E; Stanisic Trenevski J
ESMO Open; 2020 Sep; 5(5):e000850. PubMed ID: 32998966
[TBL] [Abstract][Full Text] [Related]
33. Cost analysis of palliative care for terminally ill cancer patients in the UK after switching from weak to strong opioids. Palliative Care Advisory Committee.
Guest JF; Hart WM; Cookson RF
Pharmacoeconomics; 1998 Sep; 14(3):285-97. PubMed ID: 10186467
[TBL] [Abstract][Full Text] [Related]
34. Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis.
Bristow RE; Santillan A; Diaz-Montes TP; Gardner GJ; Giuntoli RL; Meisner BC; Frick KD; Armstrong DK
Cancer; 2007 Apr; 109(8):1513-22. PubMed ID: 17354232
[TBL] [Abstract][Full Text] [Related]
35. Can we maximize both value and quality in gynecologic cancer care? A work in progress.
Havrilesky LJ; Fountain C
Am Soc Clin Oncol Educ Book; 2014; ():e268-75. PubMed ID: 24857112
[TBL] [Abstract][Full Text] [Related]
36. Health in the central and eastern countries of the WHO European Region: an overview.
Nanda A; Nossikov A; Prokhorskas R; Shabanah MH
World Health Stat Q; 1993; 46(3):158-65. PubMed ID: 8017072
[TBL] [Abstract][Full Text] [Related]
37. Optimizing treatment for patients with metastatic renal cell carcinoma in the Central and Eastern European region.
Vrdoljak E; Ciuleanu T; Kharkevich G; Mardiak J; Mego M; Padrik P; Petruželka L; Purkalne G; Shparyk Y; Skrbinc B; Szczylik C; Torday L
Expert Opin Pharmacother; 2012 Feb; 13(2):159-74. PubMed ID: 22195646
[TBL] [Abstract][Full Text] [Related]
38. Economic issues in lung cancer: a review.
Goodwin PJ; Shepherd FA
J Clin Oncol; 1998 Dec; 16(12):3900-12. PubMed ID: 9850036
[TBL] [Abstract][Full Text] [Related]
39. A review of cost-effectiveness studies in ovarian cancer.
Sfakianos GP; Havrilesky LJ
Cancer Control; 2011 Jan; 18(1):59-64. PubMed ID: 21273981
[TBL] [Abstract][Full Text] [Related]
40. Cost-of-illness studies in nine Central and Eastern European countries.
Brodszky V; Beretzky Z; Baji P; Rencz F; Péntek M; Rotar A; Tachkov K; Mayer S; Simon J; Niewada M; Hren R; Gulácsi L
Eur J Health Econ; 2019 Jun; 20(Suppl 1):155-172. PubMed ID: 31104219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
